Abstract. Autosomal dominant disorder Legius syndrome (NF1-like syndrome) shows phenotype features that overlap with neurofibromatosis type 1 (NF1), such as CALMs, freckling, macrocephaly and learning disability. Mutation analysis provides an important tool in order to distinguish two entities that have different clinical implications. We analyzed SPRED1 gene by cDNA and/or gDNA sequencing in a cohort of 46 Slovak patients in whom previously NF1 mutation was excluded. In one case we identified a nonsense mutation c.46C>T (p.Arg16*) in exon 2 of SPRED1 gene, confirming diagnosis of Legius syndrome. This mutation was reported previously.
Introduction
Both neurofibromatosis type 1 (NF1, OMIM #162200) and Legius syndrome (NF1-like syndrome, OMIM #611431) belong to so called rasopathies, the diseases characterized by mutations in the genes involved in RAS-mito gen-activated protein kinase (RAS-MAPK) pathway (Zenker 2011) . The main clinical features of Legius syndrome, such as café au lait macules (CALMs), freckling, macrocephaly and learning disability, overlap with NF1. However, so far no neurofibromas, bone lesions, optical gliomas, Lish nodules, or malignant peripheral nerve sheath tumors were reported in Legius syndrome individuals, while they are rather typical for NF1 (NIH 1988 , Brems et al. 2007 Denayer et al. 2008 Denayer et al. , 2011 Messiaen et al. 2009; Pasmant et al. 2009; Spurlock et al. 2009; Muram-Zborovski et al. 2010; Laycock-van Spyk et al. 2011) . NF1 patients usually carry germline mutation within NF1 -one of the largest human genes composed of 60 exons (17.q11.2, 280kb). Product of this gene, a tumor supressor protein neurofibromin, plays key role in negative regulation of RAS-MAPK signal pathway, where it functions as inhibitor of Ras via Ras-GTPase domain (Kern and Winter 2006; Stevenson et al. 2008) . Instead, Legius syndrom is caused by mutations in SPRED1 (Sprouty-related, EVH1 domain containing 1), a small gene (15q13.2, 104.4 kb) (Kato et al. 2003 ) divided in seven exons that code for 7255bp long transcript and protein monomer of 444 amino acids (Brems et al. 2007 ). The SPRED1 protein bound to Ras forms an active SPRED-Ras complex, which suppresses Raf phosphorylation and activation, thus, inhibits MAPK signal pathway (Wakioka et al. 2001) . Recently it has been shown that SPRED1 inhibits the Ras-ERK pathway by recruiting neurofibromin to Ras through the EVH1-GRD interaction (Hirata et al. 2016 ).
Previously we analyzed 167 Slovak patients showing symptoms compatible with NF1 for the presence of the NF1 gene mutations by sequencing of the entire NF1 coding region and MLPA analysis (Nemethova et al. 2013) . In 46 of them, no NF1 mutation was identified. In present report, we performed SPRED1 gene mutation analysis in these cases. In order to spot also possible untypical Legius syndrome Variability in individual SPRED1 polymorphic variants is shown. Twelve patients analyzed by both the cDNA and gDNA sequencing are indicated by asterisk (*). Individual patient P62 carries Arg16* mutation. In 31 cases (67.4%) only CALMs or freckling were found, thus, the phenotype compatible with Legius syndrome; 11 patients manifest also other features reported to be typical for NF1 but not for Legius syndrome, and 4 patients showed only one symptom, Lish nodules or optical glioma, which up to now have not been described in Legius syndrome. NA, not analyzed; CALMs, café au lait macules; FR, freckling; NFB, neurofibroma; OPG, optic pathway glioma; LD, learning disability; LN, Lisch nodule; WS, wrong stature; f, female; m, male. individuals, we analysed all of NF1 mutation-negative cases, irrespective of the clinical indications (Table 1) .
Methods
SPRED1 gene analysis was performed by sequencing of gDNA only (13 cases), cDNA only (21 cases), whereas in 12 patients both gDNA and cDNA was analyzed (Table 1) . Direct sequencing was performed employing Big Die® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and genetic analyzer ABI PRISM® 3130xl (Applied Biosystems). PCR primers are summarized in Supplementary Table S1 . SPRED1 reference sequence NM_152594.2 from Ensemble database was used for variant description. In 42 individuals, MLPA analysis was performed using SALSA P295 SPRED1 probemix (MRC Holland).
Results and Discussion
In patient P62 we identified SPRED1 nonsense mutation c.46C>T (p.Arg16*) (Table 1, Figure 1A ) that leads into premature stop codon within EVH1 domain ( Figure 1B ), thus we report the first genetically confirmed Slovak patient with Legius syndrome. MLPA (multiplex ligation-dependent probe amplification analysis) did not show intragenic deletion, duplication or microdeletions in any of the analyzed individuals (Table 1 ). The incidence of SPRED1 mutations in Slovak cohort of the NF1 mutation-negative cases with NF1 features is 1/46 (2.17%). If we take into account only cases with clinical features compatible with Legius syndrome, the number is even higher: 1/31 (3.2%). Table 1 summarizes also variability in 11 SNPs already described in dbSNP database and ARUP as well as one novel intronic variant c.684+50_648+53delATAG insTTAAATT-AGTA ( Table 1) that we found present in 96% (24/25) of patients in homozygous or heterozygous state. This variant was found also in 4/8 individuals tested for a SPRED1 mutation in Austria (Katharina Wimmer 2015, personal communication) .
Although a possible role of tested variants in Legius syndrome has not been shown so far we wanted to compare the allele frequencies in our population to those published elsewhere. We compared the global minor allele frequency (MAF) of the studied variants as indicated in dbSNP database (http://www.ncbi.nlm.nih.gov/projects/SNP/), in NHLBI GO Exome Sequencing Project (ESP) (http://evs. gs.washington.edu/EVS/) to that observed in our cohort of patient (Supplementary Table S2 ). In our cohort we did not observe presence of minor alleles in variants rs12148911 (c.417C>T, p.Asp139=), rs1879937 (c.423+105C>G) and rs7181472 (c.582+ 52A>G). The frequency of the minor allele A in variant c.582+52A>G in our patients was comparable only with prevalence in European population. The occurrence of minor allele in remaining seven polymorphisms in our patients was comparable to global MAF. In one case, P28, we found the presence of A allele of a rare synonymous variant c.939G>A, p.Thr313= (global frequency 0.06, Table 1,  Supplementary Table S2 ).
The first Legius syndrom patient in Slovakia is a 21 years old male, who shows 9 CALMs and learning disability. Mutation Arg16* was reported previously in 10 cases who showed freckling, macrocephaly, hypertelorism, and monoblastic acute leukemia together with different number of CALMs (Spurlock et al. 2007 (Spurlock et al. , 2009 Messiaen et al. 2009; Pasmant et al. 2009 Pasmant et al. , 2015 Spencer et al. 2011; LOVD database 2015) . Thus, there seem to be no correlation between the presence of this mutation and some specific phenotype in the patients. NF1 but not Legius syndrome patients show increased risk for malignance ). Importance of exact diagnosis is evident in order to choose relevant clinical follow up for individual patients. Since some NF1-specific symptoms develop at advanced age, in young patients the NF1 and SPRED1 mutation analysis can help to distinguish two entities at early stage. If NF1 is confirmed by the presence of the NF1 mutation, it is necessary to monitor the patient by clinical follow up and regular controls. Follow up can be more moderate in Legius syndrome cases instead. Table S1 . List of the PCR primers used for amplification and sequencing of the individual SPR exons and short flanking intronic sequences from patients' gDNA, as well as of the coding re fragments from cDNA PCR primers and conditions were described by Brems et al. (2007) except for one pair designed by us (3F and 3R, labelled by asterisk *). Primers used for PCR amplification of individual exons/fragments were used also for direct sequencing. PCR primers and conditions were described by Brems et al. (2007) except for one pair designed by us (3F and 3R, labelled by asterisk *). Primers used for PCR amplification of individual exons/fragments were used also for direct sequencing. 
